Sirolimus
- Generic Name
- Sirolimus
- Brand Names
- Fyarro, Hyftor, Rapamune
- Drug Type
- Small Molecule
- Chemical Formula
- C51H79NO13
- CAS Number
- 53123-88-9
- Unique Ingredient Identifier
- W36ZG6FT64
- Background
Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria Streptomyces hygroscopicus, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after its potent antitumor and immunosuppressive a...
- Indication
Sirolimus is indicated for the prophylaxis of organ rejection in patients aged 13 years or older receiving renal transplants. In patients at low-to moderate-immunologic risk, it is recommended that sirolimus be used initially in a regimen with cyclosporine and corticosteroids; cyclosporine should be withdrawn two to four months after transplantation. In pati...
- Associated Conditions
- Chordomas, Facial Angiofibroma, Graft-versus-host Disease (GVHD), Heart Transplant Rejection, Liver Transplant Rejection, Lung Transplant Rejection, Lymphangioleiomyomatosis (LAM), Renal Angiomyolipomas, Transplanted Organ Rejection, Metastatic malignant Perivascular Epithelioid Cell Neoplasms, Unresectable, locally advanced malignant Perivascular Epithelioid Cell Neoplasms
- Associated Therapies
- -
Tacrolimus and Sirolimus as Prophylaxis After Allogenic Non-myeloablative Peripheral Blood Stem Cell Transplantation
- Conditions
- First Posted Date
- 2006-01-26
- Last Posted Date
- 2014-05-12
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 31
- Registration Number
- NCT00282282
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Study Evaluating Sirolimus in the Treatment of Kidney Transplant
- Conditions
- First Posted Date
- 2006-01-25
- Last Posted Date
- 2007-03-22
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Target Recruit Count
- 100
- Registration Number
- NCT00282217
Individualized Drug Treatment for Treating Patients With Pancreatic Cancer
- First Posted Date
- 2006-01-13
- Last Posted Date
- 2018-10-24
- Target Recruit Count
- 249
- Registration Number
- NCT00276744
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
The Comparison of Tacrolimus and Sirolimus Immunosuppression Based Drug Regimens in Kidney Transplant Recipients
- Conditions
- Interventions
- First Posted Date
- 2006-01-12
- Last Posted Date
- 2011-12-08
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 165
- Registration Number
- NCT00275535
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
The Comparison of Three Different Immunosuppressant Regimens in Kidney Transplant Recipients.
- Conditions
- First Posted Date
- 2006-01-12
- Last Posted Date
- 2010-01-20
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 16
- Registration Number
- NCT00275522
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Study Comparing Two Sirolimus Regimens vs. Tacrolimus and Mycophenolate Mofetil Regimen in Kidney Transplant Recipients
- Conditions
- First Posted Date
- 2005-12-15
- Last Posted Date
- 2007-12-27
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Target Recruit Count
- 420
- Registration Number
- NCT00266123
Study Comparing Two Immunosuppressive Regimens in De Novo Renal Allograft Recipients
- Conditions
- First Posted Date
- 2005-12-05
- Last Posted Date
- 2006-05-19
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Target Recruit Count
- 160
- Registration Number
- NCT00261820
Study Evaluating Two Different Sirolimus-based Immunosuppressive Regimens in Elderly Kidney Transplant Recipients
- Conditions
- First Posted Date
- 2005-11-16
- Last Posted Date
- 2012-01-31
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Target Recruit Count
- 66
- Registration Number
- NCT00254709
Rapamycin vs Methotrexate in Diffuse SSc
- First Posted Date
- 2005-10-18
- Last Posted Date
- 2016-04-11
- Lead Sponsor
- University of California, Los Angeles
- Target Recruit Count
- 17
- Registration Number
- NCT00241189
- Locations
- 🇺🇸
Philip Clements, MD, Los Angeles, California, United States
Safety in Immunomodulatory Functions of Alemtuzumab (Campath) in Pediatric Kidney Transplantation Recipients
- Conditions
- Interventions
- First Posted Date
- 2005-10-18
- Last Posted Date
- 2017-01-02
- Target Recruit Count
- 35
- Registration Number
- NCT00240994
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
🇺🇸Children's Hospital, Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸Children's Hospital, Boston, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.